{"product_id":"alxo-five-forces","title":"(ALXO) ALX Oncology Holdings Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ALX Oncology Holdings Inc. Porter's Five Forces Analysis helps you assess the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the analysis, so you can review the content before buying. Purchase the full version for the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized biologics vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. relies on specialized biologics vendors for cell lines, assays, reagents, and GMP-grade inputs, and these items are hard to swap once a study starts. That gives suppliers leverage because ALX Oncology Holdings Inc. is still clinical-stage and must meet tight quality and traceability rules. In immuno-oncology, even small delays or batch failures can slow trials and lift costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on CRO partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is still clinical-stage, so it relies on CRO partners for trial ops, data, and regulatory work. In oncology, late-stage studies can span dozens of sites and cost tens of millions of dollars, so strong CROs can demand better pricing and terms when timelines are tight. That gives suppliers meaningful bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing bottlenecks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology faces a high supplier bargaining power because biologics GMP drug-substance and fill-finish slots are scarce, costly, and often booked months ahead. If ALX Oncology needs capacity for ALX148 or follow-on assets, it may have few qualified alternatives, so manufacturers can push prices and terms. Any delay, batch failure, or rework can slip trial timelines and raise cash burn fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicense and IP dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. is still dependent on licensed IP and external platforms for parts of its pipeline, so suppliers of patents and know-how have real leverage over access, timing, and economics. In FY2025, that kind of dependence mattered more because ALX Oncology remained a clinical-stage company, with value tied to continuing rights rather than owned commercial assets.\u003c\/p\u003e\n\u003cp\u003eThose counterparties can shape milestone payments, royalty rates, and commercial field rights, which can squeeze margins before any product launch. If a license is narrowed or lost, the pipeline can slow fast, and replacement rights are hard to secure on the same terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicense holders can set milestones and royalties.\u003c\/li\u003e\n\u003cli\u003eExternal IP can block pipeline access.\u003c\/li\u003e\n\u003cli\u003eRights loss can delay or cut commercialization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eModerate supplier concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. depends on a limited pool of GMP-qualified suppliers for cell-line, assay, and clinical-trial materials, so supplier power stays moderate to high. In biotech, switching vendors can take months because each change needs validation and comparability testing, which raises time and cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew qualified biotech suppliers\u003c\/li\u003e\n\u003cli\u003eSwitching needs revalidation\u003c\/li\u003e\n\u003cli\u003eDelays lift supplier leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis matters more at ALX Oncology Holdings Inc.’s stage because one supplier miss can slow a program and push up R\u0026amp;D spend. So even with no single supplier dominating, the concentration of compliant providers keeps bargaining power above normal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology Faces Strong Supplier Leverage in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. has high supplier power because FY2025 it still depended on GMP inputs, CROs, and licensed IP, and each switch needs revalidation. For clinical-stage biotech, scarce fill-finish slots and qualified vendors can push up cost and delay trials. That makes suppliers able to press on price, timing, and terms.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey supplier factor\u003c\/th\u003e\n\u003cth\u003eFY2025 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP inputs\u003c\/td\u003e\n\u003ctd\u003eHard to replace\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO support\u003c\/td\u003e\n\u003ctd\u003ePricing leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed IP\u003c\/td\u003e\n\u003ctd\u003eMilestone and royalty power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTailored to ALX Oncology Holdings Inc., it gauges supplier, buyer, rival, substitute, and entry pressures shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick Porter’s Five Forces snapshot for ALX Oncology—cutting through competitive noise to show the real strategic risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for ALX Oncology Holdings Inc., helping validate key claims and support faster, better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow direct patient power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients rarely set oncology drug prices directly, so ALX Oncology Holdings Inc. faces low direct patient power. Access runs through physicians, hospitals, and insurers, and ALX reported $194.8 million in cash, cash equivalents, and short-term investments at Q1 2025, underscoring a development-stage model where payer and provider gatekeepers matter more than end users.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh payer influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh payer influence is a real barrier for ALX Oncology Holdings Inc. if it commercializes; in the U.S., Medicare Part B usually pays 80% of many infused cancer drugs after the deductible, so coverage and reimbursement can make or break uptake. Oncology spending keeps rising, and payers push hard on price, prior auth, and formulary access when efficacy is not clearly better than cheaper options. That can squeeze ALX Oncology Holdings Inc. pricing power fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong trial site leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial sites and investigators have real leverage in oncology because they control patient recruitment and protocol execution, and the best sites can choose among many competing studies. With cancer trials making up a large share of the global pipeline, ALX Oncology Holdings Inc. must offer fast startup, clear budgets, and strong support to win top sites and keep enrollment moving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner dependence on pharma buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartner dependence on pharma buyers is high for ALX Oncology Holdings Inc. With no product sales in FY2025, the main value path is out-licensing, co-development, or a sale to a larger pharma group. Before pivotal data, strategic buyers can press hard on price because they have many other pipeline assets to choose from.\u003c\/p\u003e\n\u003cp\u003eThat means bargaining power sits with the buyer, not ALX Oncology Holdings Inc., until the program is de-risked. In oncology, large pharma keeps multiple shot-on-goal deals open, so early assets often face lower upfront terms and more milestone-heavy structures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2025: no product revenue\u003c\/li\u003e\n\u003cli\u003eBest exit: licensing, co-dev, or M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eBuyer power rises before pivotal data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEvidence-driven buying behavior\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology buyers are evidence-first: they will only switch from standard of care if ALX Oncology Holdings Inc. can show clear gains in response, safety, or survival. With ALX148 still a development asset, customer power stays high near launch because hospitals and payers can choose from many competing immuno-oncology combinations, so weak data would cap adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClear benefit beats brand loyalty.\u003c\/li\u003e\n\u003cli\u003eWeak response rates cut uptake fast.\u003c\/li\u003e\n\u003cli\u003eSafety and survival data drive switching.\u003c\/li\u003e\n\u003cli\u003eHigh payer scrutiny raises buyer power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf ALX148 cannot beat entrenched regimens on outcomes that matter, buyers can simply stay with current therapies and keep pricing pressure high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology Faces High Buyer Power Amid Zero FY2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer power is high for ALX Oncology Holdings Inc. because patients do not buy directly, while payers, hospitals, and trial sites control access, pricing, and enrollment. FY2025 had no product revenue, so buyers can still press hard on terms until ALX148 or another asset proves clear clinical value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 cash and investments\u003c\/td\u003e\n\u003ctd\u003e$194.8 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 product revenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer leverage\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eALX Oncology Holdings Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview of the ALX Oncology Holdings Inc. Porter’s Five Forces Analysis is the exact document you’ll receive after purchase—no placeholders, no changes. It’s a fully formatted, ready-to-use file that you can download instantly once your payment is complete. What you see here is what you get, so you can buy with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrowded CD47 field\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology competes in a crowded CD47 and macrophage-targeting field, where multiple biotech and large oncology companies are testing the same innate-immunity thesis. Rivalry is fierce because several programs have already reached phase 1 to phase 3, so each firm is fighting for the same patients, data, and partners. In a space this dense, clinical setbacks or wins can quickly reset the leader board.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMany combination-trial competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc.’s lead asset faces crowded combination testing across blood cancers and solid tumors, where many sponsors are pairing checkpoint, HER2, and other immune-oncology drugs in the same indications. That means the same patients, sites, and investigators are often courted by several trials at once. In 2025, this kind of overlap can slow enrollment and raise site costs, even for well-differentiated programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFast-moving innovation cycle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. faces high rivalry because oncology data can rerate a program in weeks, not years. A strong phase 1\/2 readout can pull away investor cash, partner interest, and trial sites from weaker mechanisms, while clinical-stage companies often have limited revenue to cushion that shift. That keeps pressure high on ALX Oncology Holdings Inc. to show clear efficacy and safety fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBig pharma and biotech overlap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBig pharma and biotech both crowd immuno-oncology, so ALX Oncology fights on two fronts. Merck’s Keytruda posted $29.5 billion in 2024 sales, showing the scale of big-firm capital and reach, while smaller biotechs can still move faster on new mechanisms. That split keeps rivalry high and raises the bar for ALX Oncology’s trial data and deal-making.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig pharma brings cash and sales force.\u003c\/li\u003e\n\u003cli\u003eBiotechs bring speed and new biology.\u003c\/li\u003e\n\u003cli\u003eALX Oncology faces pressure from both.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh differentiation hurdle\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eALX Oncology Holdings Inc. faces a high differentiation hurdle because many cancer programs chase the same tumors and biomarkers, so rivals can look similar fast. With one lead asset, evorpacept, still in clinical development and no approved product, ALX must show clearer efficacy, safer dosing, or easier use to win deal value and future pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame patient pools raise rivalry\u003c\/li\u003e\n\u003cli\u003eProof must beat efficacy and safety\u003c\/li\u003e\n\u003cli\u003eNo approval weakens pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALX Oncology Faces Fierce Rivalry in a Crowded Cancer Race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for ALX Oncology Holdings Inc. because CD47\/innate-immunity rivals and large oncology firms chase the same blood-cancer and solid-tumor trials. Merck’s Keytruda made $29.5 billion in 2024, showing how much capital and reach incumbents have. With only clinical-stage assets, ALX Oncology must win on efficacy, safety, and speed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket crowding\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig-pharma benchmark\u003c\/td\u003e\n\u003ctd\u003eKeytruda $29.5B 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard-of-care therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard-of-care therapies are a strong substitute for ALX Oncology Holdings Inc.’s experimental immunotherapies because many cancers can already be treated with chemotherapy, targeted therapy, radiation, or surgery. In 2025, proven regimens still dominate care when they work and are reimbursed, which lowers switching pressure for doctors and patients. With about 20 million new cancer cases worldwide each year, even small gains in efficacy or cost can decide whether a novel drug gets used.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther immuno-oncology classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCheckpoint inhibitors, bispecific antibodies, ADCs, and CAR-T therapies all target the same cancer need, so ALX Oncology Holdings Inc. faces high substitution risk. In 2025, pembrolizumab stayed a blockbuster with about $29.5 billion in 2024 sales, showing how clinicians back the strongest data. If a rival class shows better survival or safety, physicians can switch fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncremental combo alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALX148 is still being tested mainly in Phase 2\/3 combination regimens, so rival combos can move in fast. If another regimen matches efficacy but cuts grade 3\/4 safety events or simplifies dosing to fewer infusions, doctors can switch. In oncology, even a 1-step easier schedule can shift use away from ALX Oncology’s approach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWatch-and-wait in select cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn slower-moving cancers and earlier settings, clinicians can choose active surveillance instead of immediate treatment, so novel agents like ALX Oncology Holdings Inc. face a real substitute in \"watch-and-wait\" care. When benefit-risk is unclear, supportive care can preserve quality of life and delay drug use, which cuts near-term demand in some segments. That matters more for early lines, where the treatment bar is high and timing is flexible.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eActive surveillance can replace immediate therapy.\u003c\/li\u003e\n\u003cli\u003eSupportive care delays novel-agent uptake.\u003c\/li\u003e\n\u003cli\u003eUnclear benefit-risk weakens demand now.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiomarker-driven replacement risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs precision oncology deepens, biomarker matching can push patients toward better-fit drugs, so ALX Oncology Holdings Inc. can be bypassed when another therapy matches the tumor profile more closely. This is a real threat in a market where over 80% of late-stage cancer trials now use biomarkers or molecular selection. The more personalized treatment choice gets, the easier substitution becomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBetter biomarker fit can shift demand away.\u003c\/li\u003e\n\u003cli\u003eMolecular subtype matters more than broad labels.\u003c\/li\u003e\n\u003cli\u003eSubstitution risk rises with personalization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Substitute Threat Weighs on ALX Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for ALX Oncology Holdings Inc. because standard cancer care, rival immunotherapies, and watch-and-wait care can all replace its experimental drugs. In 2025, pembrolizumab still showed the scale of that pressure with about $29.5 billion in 2024 sales, while over 80% of late-stage cancer trials use biomarker selection, making switching easier when another therapy fits better.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandard care\u003c\/td\u003e\n\u003ctd\u003eAlready works in many cancers\u003c\/td\u003e\n\u003ctd\u003e20 million new cases yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther immunotherapies\u003c\/td\u003e\n\u003ctd\u003eBetter data can win fast\u003c\/td\u003e\n\u003ctd\u003eKey rival sales: $29.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurveillance\/supportive care\u003c\/td\u003e\n\u003ctd\u003eDelays or avoids drug use\u003c\/td\u003e\n\u003ctd\u003eStrong in early-line settings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capital requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh capital requirements make new entry into ALX Oncology Holdings Inc.'s field hard. Building a clinical-stage oncology pipeline can cost well over $1 billion and take 10+ years before revenue, so entrants must fund research, trials, and manufacturing long before cash comes in.\u003c\/p\u003e\n\u003cp\u003eThat spending hurdle is a major barrier, especially in a market where ALX Oncology Holdings Inc. already carries the cost and risk of late-stage development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor ALX Oncology Holdings Inc., regulatory complexity keeps the threat of new entrants low. Drug makers must prove safety, efficacy, and GMP manufacturing quality; the FDA approved only 50 novel drugs in 2024, after 55 in 2023, showing a tight gate. A single setback can erase years and hundreds of millions of dollars, so inexperienced firms face a steep barrier.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeed for scientific expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmuno-oncology is science heavy: one late-stage trial can enroll hundreds of patients and take years, so credible biology and translational data matter. Without strong scientific teams, new entrants struggle to win trial sites, patients, and Big Pharma partners. That makes scientific expertise a high barrier to entry for ALX Oncology Holdings Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and licensing barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIP and licensing walls are high in CD47, because new entrants need patents, target access, antibody know-how, and often platform licenses. As of 2025, no FDA-approved CD47 drug existed, which shows how hard it is to move from science to market. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved CD47 drug yet.\u003c\/li\u003e\n\u003cli\u003ePatents can block fast entry.\u003c\/li\u003e\n\u003cli\u003eLicenses control key targets.\u003c\/li\u003e\n\u003cli\u003eManufacturing know-how adds friction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStill possible via biotech startups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStill, the barrier is not a wall: venture-backed biotech startups can still enter oncology with novel platforms, and academic spinouts keep surfacing around new targets. In 2025, oncology remained one of the most funded biotech areas, but Phase 1 to approval often still takes 7 to 10 years and costs hundreds of millions, so entry is possible but hard. For ALX Oncology Holdings Inc., the threat is real, yet capped by cash burn, science risk, and trial time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew platforms can still break in.\u003c\/li\u003e\n\u003cli\u003eFunding supports early entry.\u003c\/li\u003e\n\u003cli\u003eTime, cost, and risk stay high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Entry Threat Protects ALX Oncology’s CD47 Niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for ALX Oncology Holdings Inc. stays low because biotech entry is capital-heavy, slow, and heavily regulated. FDA novel drug approvals were 50 in 2024 versus 55 in 2023, and CD47 still has no approved drug, so new firms face long odds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel approvals\u003c\/td\u003e\n\u003ctd\u003e50 in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCD47 approvals\u003c\/td\u003e\n\u003ctd\u003e0 approved drugs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment timeline\u003c\/td\u003e\n\u003ctd\u003e7-10 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233982030089,"sku":"alxo-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/alxo-five-forces.webp?v=1785710506","url":"https:\/\/dcfanalyst.com\/products\/alxo-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}